| DC20080 |
AT-1002
Featured
|
AT-1002, a 6-mer synthetic peptide, is a tight junction regulator and absorption enhancer. |
|
| DC2015 |
AT-101 (AT101) |
AT-101 is a BH3 mimetic known to be a potent inhibitor of antiapoptotic Bcl-2 family members. |
|
| DC20699 |
AT-130
Featured
|
AT-130 is a potent inhibitor of HBV capsid assembly, inhibits wild-type HBV replication with IC50 of 2.4 uM. |
|
| DC20698 |
AT-403 |
AT-403 (AT403) is a potent, highly selective, nonpeptide NOP agonist with pEC50 of 9.45. |
|
| DC9395 |
AT7519 (trifluoroacetate) |
AT7519 trifluoroacetate is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM; less potent to CDK3 and little active to CDK7. |
|
| DC9336 |
AT7867 (dihydrochloride) |
AT7867 Hcl is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively; little activity outside the AGC kinase family.
|
|
| DC23554 |
AT791 |
AT791 is a novel orally available, small molecule inhibitor of TLR7 and TLR9 with IC50 of 3.33 uM and 0.04 uM respectively, inhibits DNA-TLR9 interaction in vitro. |
|
| DC11889 |
Atabecestat
Featured
|
Atabecestat (JNJ-54861911, JNJ54861911) is a novel potent, oral beta-secretase (BACE) inhibitor for treatment of Alzheimer's Disease. |
|
| DC21122 |
Ataciguat sodium |
Ataciguat (HMR-1766) is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.51 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC. |
|
| DC21121 |
Ataciguat
Featured
|
Ataciguat (HMR-1766) is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.51 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC. |
|
| DC23606 |
Atagabalin |
Atagabalin (PD 0200390) is a novel ligand of the voltage-dependent calcium channel (VDCC) α2δ subunit (1 and 2) for treatment for insomnia.. |
|
| DC9480 |
Atazanavir (sulfate) |
Atazanavir sulfate is a sulfate salt form of atazanavir that is an highly potent HIV-1 protease inhibitor.
|
|
| DC10921 |
ATH686
Featured
|
ATH686 (ATH-686) is a potent and selective, second-generation inhibitor of mutant FLT3 protein kinase. |
|
| DC9878 |
ATI-2341 |
ATI-2341, pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is an allosteric agonist activating the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. |
|
| DC21656 |
Atiprimod |
Atiprimod (SKF 106615, Azaspirane) is a potent, orally bioavailable JAK2 inhibitor, inhibits phosphorylation of JAK2 and the downstream STAT3 and STAT5 pathways. |
|
| DC21657 |
Atiprimod dihydrochloride |
Atiprimod (SKF 106615, Azaspirane) is a potent, orally bioavailable JAK2 inhibitor, inhibits phosphorylation of JAK2 and the downstream STAT3 and STAT5 pathways. |
|
| DC20033 |
ATM Inhibitor-1 |
ATM Inhibitor-1 is a highly potent, selective and orally active ATM inhibitor, with an IC50 of 0.7 nM, shows weak activity against mTOR (IC50, 21 μM), DNAPK (IC50, 2.8 μM), PI3Kα (IC50, 3.8 μM), PI3Kβ (IC50, 10.3 μM), PI3Kγ (IC50, 3 μM) and PI3Kδ (IC50, 0 |
|
| DC12627 |
ATM-3507 |
ATM-3507 (ATM3507) is a small molecule inhibitor of Tpm3.1 tropomyosin isoform, disrupts Tpm3.1-containing microfilaments in SK-N-SH cells at 5 uM. |
|
| DC7709 |
ATN-161
Featured
|
ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model. |
|
| DC23607 |
Atomoxetine |
Atomoxetine ((R)-Tomoxetine. |
|
| DCAPI1390 |
Atovaquone (Atavaquone)
Featured
|
Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia. |
|
| DC11095 |
ATR-101 free base |
ATR-101 (PD-132301, Nevanimibe) is a selective and potent inhibitor of ACAT1 with IC50 of 52 nM. |
|
| DC22775 |
ATR-101 |
ATR-101 (PD-132301, Nevanimibe) is a selective and potent inhibitor of ACAT1 with IC50 of 52 nM. |
|
| DC22004 |
ATV399 |
ATV399 (ATV-399) is a novel small molecule that dose-dependently reduces the cleaved caspase9 levels with IC50 of 3.3 uM, inhibits dimerization of iNOS. |
|
| DC20114 |
ATWLPPR Peptide TFA |
ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF165 binding to NRP-1, used in the research of angiogenesis. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes. |
|
| DC23401 |
AU1 |
AU1 (GSK 1379725A) is the first selective small molecule inhibitor of BPTF bromodomain (bromodomain PHD finger transcription factor) with Kd of 2.8 uM in a cell-based reporter assay, shows no binding activity for Brd4. |
|
| DC21865 |
Aumitin
Featured
|
Aumitin is a novel potent autophagy inhibitor with IC50 of 124 and 244 nM against starvation- and rapamycin- induced autophagy respectively, targets mitochondrial complex I. |
|
| DC26036 |
Aurantiamide acetate |
Aurantiamide acetate suppresses the growth of malignant gliomas in vitro and in vivo by inhibiting autophagic flux. |
|
| DC20312 |
Aurintricarboxylic acid |
Aurintricarboxylic acid (ATA) is a potent small molecule inhibitor of RISC loading with IC50 of 0.47 uM, inhibits RISC activity against transiently expressed reporters and endogenous genes. |
|
| DC20037 |
Aurora inhibitor 1 |
Aurora inhibitor 1 is a potent Aurora inhibitor with an IC50 of ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase, respectively. |
|
